Curtin Michael L, Pliushchev Marina A, Li Huan-Qiu, Torrent Maricel, Dietrich Justin D, Jakob Clarissa G, Zhu Haizhong, Zhao Hongyu, Wang Ying, Ji Zhiqin, Clark Richard F, Sarris Kathy A, Selvaraju Sujatha, Shaw Bailin, Algire Mikkel A, He Yupeng, Richardson Paul L, Sweis Ramzi F, Sun Chaohong, Chiang Gary G, Michaelides Michael R
AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States.
AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States.
Bioorg Med Chem Lett. 2017 Apr 1;27(7):1576-1583. doi: 10.1016/j.bmcl.2017.02.030. Epub 2017 Feb 20.
Herein we disclose SAR studies of a series of dimethylamino pyrrolidines which we recently reported as novel inhibitors of the PRC2 complex through disruption of EED/H3K27me3 binding. Modification of the indole and benzyl moieties of screening hit 1 provided analogs with substantially improved binding and cellular activities. This work culminated in the identification of compound 2, our nanomolar proof-of-concept (PoC) inhibitor which provided on-target tumor growth inhibition in a mouse xenograft model. X-ray crystal structures of several inhibitors bound in the EED active-site are also discussed.
在此,我们披露了一系列二甲基氨基吡咯烷的构效关系(SAR)研究,我们最近报道这些化合物是通过破坏EED/H3K27me3结合来抑制PRC2复合物的新型抑制剂。对筛选命中化合物1的吲哚和苄基部分进行修饰,得到了结合活性和细胞活性显著提高的类似物。这项工作最终确定了化合物2,这是我们的纳摩尔级概念验证(PoC)抑制剂,它在小鼠异种移植模型中实现了靶向肿瘤生长抑制。还讨论了几种抑制剂在EED活性位点的X射线晶体结构。